Navigation Links
WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
Date:11/13/2007

GERMANTOWN, Md., Nov. 13 /PRNewswire/ -- On October 26, 2007, WestChina- Frontier PharmaTech, also known as the National Chengdu Center for Safety Evaluation of Drugs (NCCSED), received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC is an internationally recognized, not-for-profit organization, which promotes the humane treatment of animals in science through voluntary accreditation and assessment programs.

As a result of an extensive on-site evaluation, AAALAC determined that the WestChina-Frontier PharmaTech possesses state-of-the-art facilities and industry-leading programs for the care and use of laboratory animals. In addition, AAALAC noted the following in its official approval letter: that "the (company has) extensive administrative support and commitment to high standards throughout the program; the well designed and implemented training program; the genuine and deep sense of collegiality among personnel within the program at all levels' the excellent Institutional animal Care and Use Committee (IACUC) process with good documentation; the special arrangements to allow outdoor exercise for dogs; (as well as) the attention to detail in the areas of sanitation and general orderliness of facilities".

"The outcome of this AAALAC site visit demonstrates the excellent collaboration efforts between NCCSED and our partner, Frontier BioSciences. While this accreditation is not a regulatory requirement, it is an important validation of the quality, responsiveness, and the credibility of our research work", said Dr. Li Wang, CEO and Director of WestChina-Frontier PharmaTech. "The AAALAC accreditation comes as a result of our efforts to improve core operational infrastructure and service capabilities. With ongoing investments in infrastructure and world class personnel, Frontier and its partners are continuously committed to quality, responsiveness, reliability, and the satisfaction of our clients' expectations", commented by Dr. Dong Xie, President of Frontier.

About Frontier BioSciences and WestChina-Frontier PharmaTech Co Ltd.

Frontier BioSciences, Inc. is a Maryland-based company that partners with WestChina-Frontier PharmaTech Co Ltd. in Chengdu, China, providing a full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries in the scientific disciplines of GLP-compliant toxicology, developmental and reproductive toxicology, pharmacology, genetic toxicology, pathology, analytical chemistry, and international regulatory guidance.

Recent investment at the Chengdu facility resulted in the recent implementation of Pathology Data Systems (PDS), which includes comprehensive and GLP-certified data capture and FDA-compliant reporting module. In response to increasing demand for study placement, expansion plans are also underway early next year for the build-out of an additional 100,000 square-foot facility, adjacent to the current facility, with 31 new small animal rooms and 34 large animal rooms, increasing testing capacity by almost 200%.


'/>"/>
SOURCE Frontier BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
5. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
6. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
7. PartsSource Awarded US Patent for PartsFinder(TM) Application
8. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
9. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
10. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
11. UMASS Medical School awarded National Childrens Study contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: